Costunolide, isolated from the stem bark of Magnolia sieboldii, is a sesquiterpene lactone that exhibits various biological and immunological actions. We investigated the induction mechanism of apoptosis by costunolide in a human B cell leukemia NALM-6 cell culture system. Costunolide (10 m mM)-induced apoptosis time-dependently increased, estimated by nuclear damage observation and flow cytometric analysis. Costunolide did not change Fas-associated factor 1 (FAF1), but the phosphorylation of Fas-associated death domain (FADD) at serine 194 increased from early treatment. The activation of caspase-8 and -9 and degradation of poly-(ADP-ribose) polymerase (PARP) was time-dependently detected by incubation with costunolide. Pretreatment of cells with caspase-3, -8 and broad spectrum caspase inhibitors significantly blocked costunolide-induced apoptosis, but caspase-9 inhibitor failed to block apoptosis. Telomerase activity was significantly suppressed after treatment with costunolide, and human telomerase reverse transcriptase (hTERT), a critical determinant of the enzyme activity of telomerase, decreased the expression of both mRNA and protein levels by costunolide. Costunolide-induced repression of telomerase was prevented by pretreatment of cells with caspase-3, -8 and broad spectrum caspase inhibitors, but caspase-9 inhibitor was no effect. These data suggest that one of the costunolide-induced apoptotic mechanisms is that the receptor-mediated pathway precedes the mitochondria-dependent pathway, caused by the inhibition of telomerase activity via suppression of hTERT in NALM-6 cells.
Costunolide, isolated from the stem bark of Magnolia sieboldii, is a sesquiterpene lactone that exhibits various biological and immunological actions. It has been reported that costunolide has anti-inflammatory, 1) anti-viral, 2) and anti-fungal properties, 3) and exhibits anti-carcinogenic activity 4) and cytotoxic effects on various human cancer cells and leukemia cells. 5) In addition to suppressing cell proliferation, costunolide was able to induce apoptotic cell death in human leukemia cell lines. [6] [7] [8] [9] [10] Apoptosis in cancer cells can be triggered by extracellular stimuli that mediate at least two apoptotic signaling pathways, so-called receptor-mediated extrinsic and mitochondria-mediated intrinsic pathways. 11) Targeting the death receptor-mediated apoptotic pathway is believed to be a novel therapeutic method for cancers, because of its selective cytotoxicity through the death receptor pathway in transformed tumor cells but not in normal cells. 12) Lee et al. suggested that the mitochondria-dependent pathway but not the receptor-mediated pathway may be involved in costunolide-induced apoptosis of the HL-60 human leukemia cell line. 6) Telomerase, a specialized ribonucleoprotein, plays an essential role in cell proliferation as a protective mechanism against the end-replication problem by adding TTAGGG repeats to telomeres. 13) Most normal human cells have no detectable telomerase activity, but it is observed in most cancer cells 14, 15) The inhibition of telomerase causes a progressive and critical reduction of telomeres, leading to a potent signal for the blockage of cell proliferation and the induction of apoptosis. 16) Targeting the inhibition of telomerase activity and induction of apoptosis might be a selective effect on cancer cells. Costunolide has been indicated to inhibit telomerase activity in human breast carcinoma cells. 17) Clinically, B cell acute lymphoblastic leukemia is now curable; however, at least 50% of adults experience treatment failure as a consequence of both drug resistance and the inability of older adults to tolerate the side effects of therapy 18) Therefore, it is desirable to develop a new type of anti-cancer drug for B cell leukemia patients, such as targeting the receptor-mediated pathway in the induction of apoptosis or inhibition of telomerase activity, to avoid side effects in chemotherapy. In this report, we investigated the induction mechanism of apoptosis by costunolide on cellular differentiation in the human B cell leukemia NALM-6 cell culture system.
MATERIALS AND METHODS

Cell Lines and Cell Culture
Human B cell leukemia NALM-6 cell lines and other human leukemia cell lines were supplied by the Cell Resource Center for Biomedical Research, Tohoku University (Sendai, Japan). Cells were routinely kept in RPMI 1640 medium supplemented with 10% fetal bovine serum and penicillin G (100 U/ml)/streptomycin (100 mg/ml) at 37°C in a humidified 5% CO 2 -95% air incubator under standard conditions. 19) Cell viability was measured by counting, excluding those cells stained with 0.2% trypan blue. To maintain exponential growth, cells were seeded at 1ϫ10 5 cells/ml and passaged every 4 to 5 d. Chemicals Costunolide and other reagents were supplied by either Sigma (St. Louis, MO, U.S.A.) or Nacalai Tesque (Kyoto, Japan) and were of the highest grade available. All cell culture reagents were obtained from Invitrogen Corp. (Carlsbad, CA, U.S.A.). Costunolide was dissolved in dimethylsulfoxide (DMSO) to make a concentration of 10 mM as a stock solution, and was used after dilution of the stock solution with DMSO. DMSO at concentrations lower than 0.5% had no effect on cell growth. Exposure to light was kept to a minimum for all drugs. Anti-human telomerase reverse transcriptase (hTERT) antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.), and other antibodies were purchased from Cell Signaling Technology (Danvers, MA, U.S.A.).
Cytotoxicity Cytotoxicity was assessed by MTT staining as described by Mosmann. 20) Cells were plated (4ϫ10 4 cells/ well) in 96-well plates (NUNC, Roskilde, Denmark) and treated with different concentrations of costunolide for each indicated time. After treatment, 10 ml of the tetrazolium compound MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) was added for 2 h at 37°C. Cells were then centrifuged (300ϫg for 5 min), and the supernatant aspirated. The cells were lysed and solubilized by the addition of 100 ml of 0.04 N HCl in isopropanol. The absorbance in each well was determined at 590 nm using an Inter-med model NJ-2300 Microplate Reader. Survival (%) was calculated relative to the control.
Detection of Apoptotic Cells Costunolide-induced apoptotic cells were estimated by nuclear damage observation and flow cytometric analysis. 21) Morphological observations of the nucleus were distinguished by fluorescence microscopy with bisbenzimide H 33342 fluorochrome trihydrochloride (H 33342) and propidium iodide (PI). Cells were collected by centrifugation, washed with phosphate-buffered saline (PBS), and stained for 10 min at room temperature in PBS containing 5 mM H 33342 or 5 mM PI. Changes in nuclear morphology were observed under a model TE 300 fluorescence microscope (Nikon, Tokyo, Japan). Apoptosis was characterized by chromatin condensation followed by the formation of multiple bodies. Necrosis was indicated by PI-stained cells. At least 300 cells were counted in each experiment, and the percentage of apoptotic and necrotic cells was calculated.
For flow cytometric analysis, cells were cultured in triplicate in 35 mm dishes at 4ϫ10 5 cells. After incubation with or without costunolide, cells were washed with PBS and collected. Cell pellets were suspended in 1 ml of 10 mg/ml RNase A containing 0.5% Triton-X 100 plus the same volume of 20 mg/ml propidium iodide and then incubated in the dark at room temperature for 30 min. Cell suspensions were filtered through a 60 mm mesh filter to determine the effect on apoptotic-characteristic, hypodiploid cells (sub-G1 peak). Data acquisition and analysis were performed on a FACScan flow cytometer (Becton Dickenson, San Jose, CA, U.S.A.).
Western Blotting Cells were washed with PBS and lysed in CelLytic M (Sigma, St. Louis, MO, U.S.A.), according to the manufacturer's instructions. Samples (30 mg) of each protein were loaded onto a 10-15% SDS-polyacrylamide gel. After electrophoresis, the protein was transferred to a PVDF membrane, blocked with blocking solution (25 mM Tris-HCl pH 7.4, 137 mM NaCl, 2.68 mM KCl and 10% skim milk) for 4 h and reacted with antibody overnight at 4°C. The membrane was then washed with blocking solution without skim milk, and incubated with horseradish peroxidase-linked secondary antibody for 1 h. After washing again, protein levels were analyzed by enhanced chemiluminescence with an ECL plus Western blotting detection system (Amersham, Arlington Heights, IL, U.S.A.).
Telomerase Activity Assay Telomerase activity was measured using a stretch PCR-based TeloChaser system (Toyobo, Tokyo, Japan) according to the manufacturer's protocol. In brief, 4ϫ10 5 cells were lysed in 50 ml lysis reagent and incubated on ice for 20 min. After centrifugation at 12000ϫg for 20 min, the DNA product was isolated and 26 cycles of PCR amplification were performed at 95°C for 30 s, at 68°C for 30 s and at 72°C for 45 s. PCR products were electrophoresed on a 10% polyacrylamide gel, and the gel was stained with ethidium bromide and imaged using an FLA-3000G image analyzer (Fujifilm, Tokyo, Japan).
Isolation of RNA and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) For the extraction of total RNA, approximately 1ϫ10 6 cells were harvested by centrifugation at 1500ϫg for 5 min and washed twice with PBS. Total RNA was isolated with ISOGEN reagent (Nippongene, Tokyo, Japan) and an RT-PCR assay was employed using SuperScript One-Step RT-PCR with Platinum Taq (Invitrogen Corp., Carlsbad, CA, U.S.A.) according to the manufacturer's protocol. The primers for hTERT (GenBank accession number: AF015950), (forward 5Ј-AAC TTG CGG AAG ACA GTG GT-3Ј, reverse 5Ј-GTG ACA CTT CAG CCG CAA GA-3Ј) were designed using genetic information processing software GENETYX ® (Genetyx Corp., Tokyo, Japan). Amplimers for b-actin (GenBank accession number: X00351) cDNA were as described elsewhere. 22) cDNA synthesis and pre-denaturation were performed for one cycle of 50°C for 30 min and 94°C for 2 min, immediately followed by 30 cycles of 15 s at 94°C (dissociation), 30 s at 60°C (primer annealing), and 1 min at 72°C (extension), followed by a final 10 min of incubation at 72°C to complete primer extension. PCR products (254-bp hTERT fragment; 336-bp b-actin fragment) were resolved by electrophoresis on a 1% agarose gel, and the gel was stained with ethidium bromide and imaged. The appearance of a single band of the correct molecular size confirmed the specificity of the PCR.
Statistical Analysis Statistical analysis of the results was performed by one-way analysis of variance (ANOVA) followed by Scheffe's F test. A p-value of Ͻ0.05 was considered significant.
RESULTS AND DISCUSSION
Induction of Cytotoxicity and Apoptosis by Costunolide First, we examined the cytotoxicity of costunolide in NALM-6 cells and several human leukemia cell lines, estimated by MTT assay ( Table 1 ). The 50% inhibited concentration of cell proliferation on incubation with costunolide for 24 h was 3.31Ϯ0.32 mM. Isolated primary human lympoid cells incubated for 24 h with costunolide up to 100 mM showed no cytotoxic effects (data not shown). In comparison with cytotoxic effect by costunolide on several human leukemia cell lines, NALM-6 cells were most susceptible in this study. Besides, costunolide was more susceptible to NALM-6 cells compared to other human leukemia cell lines in the previous reports. [6] [7] [8] [9] [10] The susceptible effect of costunolide on leukemia cells is not clear at present. Costunolide-induced cytotoxicity in several human leukemia cell lines has already been reported to involve the induction of apoptosis.
6-10) Next, we confirmed the induction of apoptosis by costunolide in NALM-6 cells. As shown in Fig. 1A , 10 mM costunolide-induced apoptosis featuring as chromatin condensation or apoptosis bodies was time-dependently increased. To further examine the effects of costunolide on apoptosis, we used flow cytometry to quantify the apoptotic state. We found that NALM-6 cells exposed to 10 mM costunolide for 2, 4, and 6 h showed 11.49, 27.48 and 49.02% apoptosis (sub-G1 peak), respectively (Fig. 1B) . The same analysis showed that the Sub-G1 peak of NALM-6 cells dose-dependently increased to 2.25, 8.28, 32.79 and 50.12% after 6 h of treatment with 2, 6, 8 and 10 mM costunolide, respectively (Fig. 1C) . These data indicate that the cytotoxic effect of costunolide is also involved in apoptosis of NALM-6 cells. Because treatment of NALM-6 cells with 10 mM costunolide resulted in apparent apoptosis, we used a concentration of costunolide of 10 mM in order to determine the early induction mechanism of apoptosis in the following experiment.
Effects of Costunolide on the Expression of Apoptosisrelated Proteins and Caspase Pathway
Apoptosis requires the transmission of apoptotic signals. Fas is a member of the tumor necrosis factor (TNF) superfamily that plays a critical role in receptor-mediating apoptosis. Fas-associated factor 1 (FAF1) is a Fas-associating molecule, which enhances Fas-mediated apoptosis.
23) The Fas-associated death domain (FADD) was originally identified as an adapter molecule linking the activated Fas receptor to the effector molecule caspase-8, 24) but phosphorylation of FADD at serine 194 did not play a role in Fas-induced apoptosis signaling. 25) We have explored that costunolide-induced apoptosis was involved in the Fas-mediated pathway using Western blotting analysis to detect FAF1, phosphorylation of FADD at serine 194, and activation of caspase-8 (Fig. 2) . Costunolide did not change FAF1, but phosphorylation of FADD at serine 194 increased from early treatment with costunolide. The activation of caspase-8 via proteolytic degradation of proenzyme into the activated form was detected in a time-dependent manner. Fas expression did not change by costunolide in this experiment (data not shown). These data suggest that costunolideinduced apoptosis is not through the Fas-mediated pathway. The phosphorylation of FADD at serine 194 has also been shown to cell cycle regulation at the G2/M transition. 25) Curiously, there was little change G2/M phase by incubation with costunolide in our results (Fig. 1B, C) . FADD and its phosphorylation respond to various biological functions. 26) The relations between costunolide-induced change of cell cycle and the effect of FADD phosphorylation remain to be elucidated. It is known that FADD contains a death domain and death effector domain on the not only Fas but also the TNF family. 27) We speculate that one of the induction mechanisms of apoptosis by costunolide is involvement of other receptormediated pathways, except Fas, and following activation of the caspase-8 pathway, but this remains unclear. On the other hand, the induction mechanism of apoptosis by costunolide demonstrated reactive oxygen species (ROS)-mediated mitochondrial permeability transition and resultant cytochrome c release in HL-60 cells.
6) The same results were shown in NALM-6 cells in our previous experiments. 28) Cleaved caspase-9 is a mitochondria-dependent apoptotic signal, detected by Western blotting analysis (Fig. 2) . These results indicate that the induction mechanism of apoptosis by costunolide is through both the receptor-mediated pathway and mitochondria-dependent pathway. Poly-(ADP-ribose) polymerase (PARP) is one of the main cleavage targets of caspase-3, which is involved in enzyme apoptosis. 29) Cleaved PARP is down-stream of caspase-8, and -9 in the apoptosis process. As shown in Fig. 2 , incubation with costunolide caused a time-dependent proteolytic cleavage of PARP, with accumulation of 89 kDa fragments during apoptosis. In order to discern essential caspases in the apoptotic pathway induced by costunolide, specific caspases inhibitors, DEVD-FMK for caspase-3 inhibitor, IETD-FMK for caspase-8 inhibitor and LEHD-FMK for caspase-9 inhibitor or a broad spectrum caspases inhibitor, Z-Asp-CH 2 -DCB, were pretreated for 1 h, and then costunolide was treated for 12 h (Fig. 3) . The inhibitors showed no cytotoxic effects themselves and no affects on necrotic cell death by costunolide. Pretreatment of cells with caspase-3, -8 and broad spectrum caspase inhibitors significantly blocked costunolide-induced apoptosis, but caspase-9 inhibitor failed to block apoptosis. These data suggest that the receptor-mediated pathway precedes the mitochondria-dependent pathway in the induction mechanism of apoptosis by cosunolide in NALM-6 cells.
Effects of Costunolide on Telomerase Activity and Expression of hTERT To examine the effect of costunolide on telomerase activity, NALM-6 cells were incubated in the absence or presence of costunolide, and telomerase activity was measured by stretch PCR (Fig. 4A) . Telomerase activity was expressed as a ladder of bands of 6 base pairs (bp) or multiples of 6 bp intervals. Compared to untreated cells, telomerase activity was significantly suppressed after treatment with costunolide in a time-dependent manner. Percentage inhibition of telomerase was calculated from band intensity and the results revealed that telomerase activity compared to untreated control cells (100%) was decreased by 94%, 89%, 21%, and 2% after treatment with 10 mM costunolide for 1, 2, 4 and 6 h, respectively. To verify the mechanism of the inhibitory effects of costunolide on telomerase activity, we investigated whether this agent could modulate the expression of the telomerase-component gene in NALM-6 cells. One of the components of telomerase, hTERT, is a critical determinant of the enzyme activity of telomerase. 30) We therefore examined changes in mRNA and protein of hTERT expression with costunolide treatment using RT-PCR and Western blotting, respectively. As indicated in Fig. 4B , hTERT mRNA expression decreased by costunolide treatment in a time-dependent manner (0 h, 100%; 1 h, 96%; 2 h, 64%; 4 h, 16%; 6 h, 14%). Similarly, hTERT protein (0, 1, 2, 4, or 6 h) also decreased (100%, 97%, 69%, 21%, and 20%, respectively) correlating with mRNA expression (Fig. 4C) . Pleschke et al. indicated that the PARP-binding site in telomerase localizes to the hTERT catalytic subunit. 31) Our data showed that costunolide caused time-dependent proteolytic cleavage of PARP (Fig. 2) , which might be degradation to hTERT (Figs. 4B, C) , and inhibition of telomerase activity (Fig. 4A) . It was reported that maintenance of telomerase function could inhibit apoptosis, 32) and repression of telomerase was an early event in the apoptotic cascade 33) ; therefore, telomerase inhibition by costunolide can be interpreted as an important event that leads to apoptosis. Finally, we have examined that costunolide-induced repression of telomerase was caused by whether trigger of apoptosis or following result of apoptosis progression in this cells. As shown in Fig. 5 , costunolide-induced repression of telomerase at incubation for 6 h (2%) was significantly prevented by pretreatment of Cells were incubated with 50 mM of each caspase inhibitor (caspase-3 inhibitor, DEVD-FMK; caspase-8 inhibitor, IETD-FMK; caspase-9 inhibitor, LEHD-FMK; broad spectrum caspase inhibitor, Z-Asp-CH 2 -DCB) for 1 h before 10 mM costunolide treatment, followed by incubation with costunolide for 12 h. Apoptosis was estimated by nuclear morphological observation, as described in Materials and Methods. Each value represents the meanϮS.E. for three different experiments performed in triplicate. * pϽ0.05 vs. 10 mM costunolide alone incubation groups. cells with caspase-3 (84%), -8 (72%) and broad spectrum caspase inhibitors (96%), but caspase-9 inhibitor was no effect (2%). Thus inhibition of caspases could block the costunolide-induced apoptosis (Fig. 3) , and their inhibition coincided with repression of telomerase by costunolide (Fig. 5) . These data imply an important role of telomerase in modulating apoptotic cell death, which may serve as a basis for designing novel anti-cancer drugs.
In conclusion, costunolide-induced cytotoxicity was through the induction of apoptosis in NALM-6 cells. The induction mechanisms of apoptosis by costunolide in cells involved the receptor-mediated pathway preceding the mitochondria-dependent pathway. Telomerase activity was significantly suppressed after treatment with costunolide, and hTERT, a critical determinant of the enzyme activity of telomerase, decreased the expression of both mRNA and protein levels by costunolide. Clinical treatment for leukemia patients involves many chemotherapeutic agents. It is preferable for chemotherapeutic agents to have few side effects, and selective cytotoxic effects on cancer cells. Our data indicate that costunolide might be a useful chemotherapeutic agent for leukemia. Further investigation is needed. Cells were incubated with 50 mM of each caspase inhibitor (caspase-3 inhibitor, DEVD-FMK; caspase-8 inhibitor, IETD-FMK; caspase-9 inhibitor, LEHD-FMK; broad spectrum caspase inhibitor, Z-Asp-CH 2 -DCB) for 1 h before 10 mM costunolide treatment, followed by incubation with costunolide for 6 h. Telomerase activity was measured by stretch PCR, as described in Materials and Methods. Similar results were obtained in three separate sets of experiments.
